Zhejiang Ausun Pharmaceutical Co Ltd (SHG:603229) — Market Cap & Net Worth
Market Cap & Net Worth: Zhejiang Ausun Pharmaceutical Co Ltd (603229)
Zhejiang Ausun Pharmaceutical Co Ltd (SHG:603229) has a market capitalization of $986.57 Million (CN¥6.74 Billion) as of June 23, 2026. Listed on the SHG stock exchange, this China-based company holds position #9117 globally and #2311 in its home market, demonstrating a -9.17% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zhejiang Ausun Pharmaceutical Co Ltd's stock price CN¥8.12 by its total outstanding shares 830297145 (830.30 Million). Review how much debt does Zhejiang Ausun Pharmaceutical Co Ltd carry to assess the company's total debt and financial obligations.
Zhejiang Ausun Pharmaceutical Co Ltd Market Cap History: 2017 to 2026
Zhejiang Ausun Pharmaceutical Co Ltd's market capitalization history from 2017 to 2026. Data shows growth from $613.22 Million to $986.57 Million (10.23% CAGR).
Zhejiang Ausun Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zhejiang Ausun Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.52x
Zhejiang Ausun Pharmaceutical Co Ltd's market cap is 1.52 times its annual revenue
Latest Price to Earnings (P/E) Ratio
9.23x
Zhejiang Ausun Pharmaceutical Co Ltd's market cap is 9.23 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $613.22 Million | $240.19 Million | $53.01 Million | 2.55x | 11.57x |
| 2018 | $414.58 Million | $243.89 Million | $43.86 Million | 1.70x | 9.45x |
| 2019 | $737.40 Million | $307.91 Million | $56.39 Million | 2.39x | 13.08x |
| 2020 | $1.87 Billion | $409.25 Million | $86.84 Million | 4.57x | 21.54x |
| 2021 | $2.24 Billion | $569.70 Million | $145.93 Million | 3.92x | 15.32x |
| 2022 | $2.05 Billion | $764.55 Million | $235.38 Million | 2.68x | 8.71x |
| 2023 | $1.60 Billion | $816.77 Million | $253.90 Million | 1.97x | 6.32x |
| 2024 | $1.21 Billion | $795.29 Million | $206.79 Million | 1.53x | 5.87x |
| 2025 | $1.21 Billion | $792.76 Million | $130.57 Million | 1.52x | 9.23x |
Competitor Companies of 603229 by Market Capitalization
Companies near Zhejiang Ausun Pharmaceutical Co Ltd in the global market cap rankings as of June 23, 2026.
Key companies related to Zhejiang Ausun Pharmaceutical Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #571 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.70 |
| #571 | Argen-X | BR:ARGX | $47.14 Billion | €773.80 |
Zhejiang Ausun Pharmaceutical Co Ltd Historical Marketcap From 2017 to 2026
Between 2017 and today, Zhejiang Ausun Pharmaceutical Co Ltd's market cap moved from $613.22 Million to $ 986.57 Million, with a yearly change of 10.23%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥986.57 Million | -18.15% |
| 2025 | CN¥1.21 Billion | -0.70% |
| 2024 | CN¥1.21 Billion | -24.38% |
| 2023 | CN¥1.60 Billion | -21.72% |
| 2022 | CN¥2.05 Billion | -8.28% |
| 2021 | CN¥2.24 Billion | +19.53% |
| 2020 | CN¥1.87 Billion | +153.60% |
| 2019 | CN¥737.40 Million | +77.87% |
| 2018 | CN¥414.58 Million | -32.39% |
| 2017 | CN¥613.22 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 22nd, 2026 the market cap of Zhejiang Ausun Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $986.57 Million USD |
| MoneyControl | $986.57 Million USD |
| MarketWatch | $986.57 Million USD |
| marketcap.company | $986.57 Million USD |
| Reuters | $986.57 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Zhejiang Ausun Pharmaceutical Co Ltd
Zhejiang Ausun Pharmaceutical Co., Ltd. engages in the research and development, process development, manufacture, and sale of APIs and pharmaceutical intermediates. It offers fluorine products, prostaglandins, antimicrobials, and oncology products. The company also provides products for liver disease, respiratory system, and cardiac and cerebral vessels, as well as CNS indications. In addition, … Read more